Get the Stockscreener App
10.60
0.47%
0.05
Pre-market:
10.70
0.10
+0.94%
Novavax Inc stock is traded at $10.60, with a volume of 4.34M.
It is up +0.47% in the last 24 hours and up +19.64% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$10.55
Open:
$10.425
24h Volume:
4.34M
Relative Volume:
0.97
Market Cap:
$1.75B
Revenue:
$596.34M
Net Income/Loss:
$-87.84M
P/E Ratio:
-17.74
EPS:
-0.5975
Net Cash Flow:
$-97.62M
1W Performance:
+6.00%
1M Performance:
+19.64%
6M Performance:
+14.47%
1Y Performance:
+22.69%
1-Day Range:
$10.38
$10.85
1-Week Range:
$9.76
$11.09
52-Week Range:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
10.60 | 1.75B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Enterprise value to EBIT forward of Novavax, Inc. – BX:NVV1 - TradingView
Novavax stock falls 2.59 percent below its yearly high - AD HOC NEWS
Novavax stock falls 2.54 percent below its yearly high - AD HOC NEWS
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax, Inc. (NVV1.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax stock gains as Q2 2026 revenue rises and vaccine focus deepens - AD HOC NEWS
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - finance.yahoo.com
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock? - finance.yahoo.com
Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act? - Yahoo Finance
Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - finance.yahoo.com
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax (NVAX) Laps the Stock Market: Here's Why - Yahoo Finance
ETFs Investing in Novavax, Inc. Stocks - TradingView
Novavax Inc Lobbyists, 2020 - opensecrets.org
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot - TradingView
Transcript : Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM - marketscreener.com
Novavax at Citi summit: partnerships extend cash runway By Investing.com - Investing.com India
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference - Yahoo Finance
Novavax at cantor healthcare conference: pivot to licensing gains steam - investing.com
Novavax at cantor healthcare conference: pivot to licensing gains steam By Investing.com - Investing.com Canada
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
NVAX: Strategic shift to licensing and Matrix-M partnerships drives growth in vaccines and oncology - TradingView
NVAX: Major pharma partnerships, Matrix-M expansion, and global commercialization drive future growth - TradingView
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):